|Bid||0.0000 x 800|
|Ask||0.0000 x 1000|
|Day's Range||2.9000 - 2.9800|
|52 Week Range||2.0400 - 9.3000|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
Cannabis News On Dec. 20, President Trump signed the Agriculture Improvement Act of 2018 into law, legalizing hemp in the U.S. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as cannabis (Cannabis sativa L.), and derivatives of cannabis with extremely low (less than 0.3% […] The post Cannabis Stock News Weekend Roundup December 23 appeared first on Market Exclusive.
CORAL GABLES, FL / ACCESSWIRE / October 24, 2018 / Many marijuana stocks took a tumble following Canada's recent cannabis industry legalization last week. Tuesday, sector stocks took another hit during ...
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Biotech stocks CASI Pharmaceuticals and Therapix Biosciences were both seeing big gains on acquisition news. CASI has acquired a U.S. FDA-approved abbreviated ...
Tesla Inc (NASDAQ: TSLA) said it will report third-quarter earnings after the closing bell Wednesday. Shares of the automaker were down 1.23% in pre-market trade. Tesla has scheduled a conference call at 5:30 p.m. Eastern time to discuss the third quarter and outlook. Law enforcement agencies defused an explosive device found in Westchester County, New […] The post Stock Market News Daily Roundup October 23 appeared first on Market Exclusive.
Canada's FSD Pharma Inc signed a letter of intent to acquire Israel's Therapix Biosciences Ltd for $48 million in stock, combining two complementary businesses focused on the research and development of cannabinoid treatments. Therapix shareholders will receive about 130 million class B subordinate shares of FSD Pharma, nearly 10 percent of the company, FSD said on Tuesday. FSD's shares will continue to be listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange and the company intends to apply to list on Nasdaq.
CSE: HUGE OTCQB: FSDDF FRA: 0K9 Transaction combines two highly complementary businesses; the significant production and distribution of medical and recreational products by FSD Pharma, and the premium ...
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Therapix Biosciences Ltd. (TRPX) is a specialty clinical-stage pharmaceutical company creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. On October 1st, TRPX shares closed at $4.57 and have since then hit an intra-day high of $7.65 (+67%). Combining PEA with THC may stimulate cannabinoid receptors, inhibit metabolic degradation, and thus increase uptake of THC.